Raymond Wadlow, MD
Raymond Wadlow, MD, is a gastrointestinal oncologist specializing in pancreatic and gastrointestinal cancers at the Inova Schar Cancer Institute in Farifax, VA. Dr. Wadlow graduated from the University of Virginia School of Medicine in 2000 and he completed internal medicine residency at the University of Pennsylvania in 2003. After his mother, the late Virginia state senator Emily Couric, died in 2001 at 54 from pancreatic cancer, Dr. Wadlow chose to pursue hematology-oncology fellowship training at the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston. After seven years as a laboratory-based physician-scientist and gastrointestinal oncologist in Boston, Dr. Wadlow worked for nine years in community practice as part of the U.S. Oncology Network. In his current position, he serves as co-director of the gastrointestinal oncology research program and program director for the Inova Schar Hematology-Oncology Fellowship. Dr. Wadlow is also the director of the high-risk pancreatic clinic at the Inova Saville Cancer Screening and Prevention Center, and a principal investigator in the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Dr. Wadlow is the author of numerous peer-reviewed publications and has dedicated his career to improving the lives of patients at risk or diagnosed with pancreatic and other gastrointestinal cancers.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Bristol Myers SquibbTopic:Colorectal CancerDate added:04/24/2023Date updated:03/07/2024Relationship end date:12/31/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Exact SciencesTopic:Colorectal CancerDate added:04/24/2023Date updated:03/07/2024Relationship end date:01/25/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:TaihoTopic:Colorectal CancerDate added:04/24/2023Date updated:03/07/2024Relationship end date:03/30/2023
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:SeagenTopic:Colorectal CancerDate added:04/24/2023Date updated:03/07/2024Relationship end date:10/25/2022
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:PfizerTopic:Colorectal CancerDate added:04/24/2023Date updated:03/07/2024Relationship end date:12/31/2023